Hypofractionated radiotherapy after conservative surgery may increase low–intermediate grade late fibrosis in breast cancer patients

Hypofractionated radiotherapy after conservative surgery may increase low–intermediate grade late fibrosis in breast cancer patients

Cinzia Digesù,1 Francesco Deodato,1 Gabriella Macchia,1 Savino Cilla,2 Martina Pieri,3 Alice Zamagni,4 Andrea Farioli,5 Milly Buwenge,4 Gabriella Ferrandina,6,* Alessio G Morganti4,* 1Radiotherapy Unit, General Oncology Unit, Fondazione Giovanni Paolo II, Campobasso, Italy; 2Medi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Digesù C, Deodato F, Macchia G, Cilla S, Pieri M, Zamagni A, Farioli A, Buwenge M, Ferrandina G, Morganti AG
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
breast cancer
radiotherapy
hypofractionation
retrospective study.
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/25ca4bb55b11401ea2cce66c2cb6489f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:25ca4bb55b11401ea2cce66c2cb6489f
record_format dspace
spelling oai:doaj.org-article:25ca4bb55b11401ea2cce66c2cb6489f2021-12-02T08:34:35ZHypofractionated radiotherapy after conservative surgery may increase low–intermediate grade late fibrosis in breast cancer patients1179-1314https://doaj.org/article/25ca4bb55b11401ea2cce66c2cb6489f2018-10-01T00:00:00Zhttps://www.dovepress.com/hypofractionated-radiotherapy-after-conservative-surgery-may-increase--peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Cinzia Digesù,1 Francesco Deodato,1 Gabriella Macchia,1 Savino Cilla,2 Martina Pieri,3 Alice Zamagni,4 Andrea Farioli,5 Milly Buwenge,4 Gabriella Ferrandina,6,* Alessio G Morganti4,* 1Radiotherapy Unit, General Oncology Unit, Fondazione Giovanni Paolo II, Campobasso, Italy; 2Medical Physics Unit, Fondazione Giovanni Paolo II, Campobasso, Italy; 3Radiotherapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; 4Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; 5Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; 6Department of Woman and Child Health, Gynecologic Oncology Unit, Fondazione “Policlinico Universitario A. Gemelli”, IRCSS, Universita’ Cattolica Sacro Cuore, Rome, Italy *These authors contributed equally to this work Aim: To compare late toxicity after postoperative hypofractionated radiotherapy (RT) and standard fractionated RT in patients with early-stage breast carcinoma.Methods: This retrospective study included 447 patients (Modulated Accelerated Radiotherapy [MARA-1]: 317 patients, and control group [CG]: 130 patients). In the CG, the whole breast received 50.4 Gy in 28 fractions (fx) using 3D-radiotherapy, plus a sequential electron boost (10 Gy in 4 fx) to tumor bed. In MARA-1 group, a forward-planned intensity-modulated radiotherapy technique with 40 Gy in 16 fx with a concomitant boost of 4 Gy to breast was used. The primary endpoint was to evaluate late toxicity, and secondary endpoints were acute toxicity, local control, and survival. ClinicalTrials.gov: NCT03461224.Results: Median follow-up was 52 months (range: 3–115 months). Late skin and subcutaneous toxicity were acceptable: 5-year actuarial cumulative incidence of Grade (G) 3 late skin toxicity was 1.5% in CG and 0.0% in MARA-1. Five-year actuarial cumulative incidence of G3 late subcutaneous toxicity was 0.8% in CG and 0.3% in MARA-1. On multivariate analysis, tobacco smoking and planning target volume were associated with an increased risk of late G1 skin toxicity (HR: 2.15, 95% CI: 1.38–3.34 and HR: 1.12, 95% CI: 1.07–1.18, respectively), whereas patients with a larger planning target volume also showed an increased risk of G1 and G2 late subcutaneous toxicity (HR: 1.14, CI 95%: 1.08–1.20 and HR: 1.14, 95% CI: 1.01–1.28, respectively). MARA-1 patients also showed an increased risk of late G1 and G2 subcutaneous toxicity (HR: 2.35, 95% CI: 1.61–3.41 and HR: 3.07, 95% CI: 1.11–8.53, respectively) compared to CG.Conclusion: In this retrospective analysis, postoperative accelerated-hypofractionated RT for early-stage-breast carcinoma was associated with higher incidence of subcutaneous side effects. However, this increase was limited to G1–G2 toxicity. In the future, development of predictive models could help in tailoring dose and fractionation based on the risk of toxicity. Keywords: breast cancer, radiotherapy, hypofractionation, retrospective studyDigesù CDeodato FMacchia GCilla SPieri MZamagni AFarioli ABuwenge MFerrandina GMorganti AGDove Medical Pressarticlebreast cancerradiotherapyhypofractionationretrospective study.Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 10, Pp 143-151 (2018)
institution DOAJ
collection DOAJ
language EN
topic breast cancer
radiotherapy
hypofractionation
retrospective study.
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle breast cancer
radiotherapy
hypofractionation
retrospective study.
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Digesù C
Deodato F
Macchia G
Cilla S
Pieri M
Zamagni A
Farioli A
Buwenge M
Ferrandina G
Morganti AG
Hypofractionated radiotherapy after conservative surgery may increase low–intermediate grade late fibrosis in breast cancer patients
description Cinzia Digesù,1 Francesco Deodato,1 Gabriella Macchia,1 Savino Cilla,2 Martina Pieri,3 Alice Zamagni,4 Andrea Farioli,5 Milly Buwenge,4 Gabriella Ferrandina,6,* Alessio G Morganti4,* 1Radiotherapy Unit, General Oncology Unit, Fondazione Giovanni Paolo II, Campobasso, Italy; 2Medical Physics Unit, Fondazione Giovanni Paolo II, Campobasso, Italy; 3Radiotherapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; 4Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy; 5Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; 6Department of Woman and Child Health, Gynecologic Oncology Unit, Fondazione “Policlinico Universitario A. Gemelli”, IRCSS, Universita’ Cattolica Sacro Cuore, Rome, Italy *These authors contributed equally to this work Aim: To compare late toxicity after postoperative hypofractionated radiotherapy (RT) and standard fractionated RT in patients with early-stage breast carcinoma.Methods: This retrospective study included 447 patients (Modulated Accelerated Radiotherapy [MARA-1]: 317 patients, and control group [CG]: 130 patients). In the CG, the whole breast received 50.4 Gy in 28 fractions (fx) using 3D-radiotherapy, plus a sequential electron boost (10 Gy in 4 fx) to tumor bed. In MARA-1 group, a forward-planned intensity-modulated radiotherapy technique with 40 Gy in 16 fx with a concomitant boost of 4 Gy to breast was used. The primary endpoint was to evaluate late toxicity, and secondary endpoints were acute toxicity, local control, and survival. ClinicalTrials.gov: NCT03461224.Results: Median follow-up was 52 months (range: 3–115 months). Late skin and subcutaneous toxicity were acceptable: 5-year actuarial cumulative incidence of Grade (G) 3 late skin toxicity was 1.5% in CG and 0.0% in MARA-1. Five-year actuarial cumulative incidence of G3 late subcutaneous toxicity was 0.8% in CG and 0.3% in MARA-1. On multivariate analysis, tobacco smoking and planning target volume were associated with an increased risk of late G1 skin toxicity (HR: 2.15, 95% CI: 1.38–3.34 and HR: 1.12, 95% CI: 1.07–1.18, respectively), whereas patients with a larger planning target volume also showed an increased risk of G1 and G2 late subcutaneous toxicity (HR: 1.14, CI 95%: 1.08–1.20 and HR: 1.14, 95% CI: 1.01–1.28, respectively). MARA-1 patients also showed an increased risk of late G1 and G2 subcutaneous toxicity (HR: 2.35, 95% CI: 1.61–3.41 and HR: 3.07, 95% CI: 1.11–8.53, respectively) compared to CG.Conclusion: In this retrospective analysis, postoperative accelerated-hypofractionated RT for early-stage-breast carcinoma was associated with higher incidence of subcutaneous side effects. However, this increase was limited to G1–G2 toxicity. In the future, development of predictive models could help in tailoring dose and fractionation based on the risk of toxicity. Keywords: breast cancer, radiotherapy, hypofractionation, retrospective study
format article
author Digesù C
Deodato F
Macchia G
Cilla S
Pieri M
Zamagni A
Farioli A
Buwenge M
Ferrandina G
Morganti AG
author_facet Digesù C
Deodato F
Macchia G
Cilla S
Pieri M
Zamagni A
Farioli A
Buwenge M
Ferrandina G
Morganti AG
author_sort Digesù C
title Hypofractionated radiotherapy after conservative surgery may increase low–intermediate grade late fibrosis in breast cancer patients
title_short Hypofractionated radiotherapy after conservative surgery may increase low–intermediate grade late fibrosis in breast cancer patients
title_full Hypofractionated radiotherapy after conservative surgery may increase low–intermediate grade late fibrosis in breast cancer patients
title_fullStr Hypofractionated radiotherapy after conservative surgery may increase low–intermediate grade late fibrosis in breast cancer patients
title_full_unstemmed Hypofractionated radiotherapy after conservative surgery may increase low–intermediate grade late fibrosis in breast cancer patients
title_sort hypofractionated radiotherapy after conservative surgery may increase low–intermediate grade late fibrosis in breast cancer patients
publisher Dove Medical Press
publishDate 2018
url https://doaj.org/article/25ca4bb55b11401ea2cce66c2cb6489f
work_keys_str_mv AT digesuc hypofractionatedradiotherapyafterconservativesurgerymayincreaselowndashintermediategradelatefibrosisinbreastcancerpatients
AT deodatof hypofractionatedradiotherapyafterconservativesurgerymayincreaselowndashintermediategradelatefibrosisinbreastcancerpatients
AT macchiag hypofractionatedradiotherapyafterconservativesurgerymayincreaselowndashintermediategradelatefibrosisinbreastcancerpatients
AT cillas hypofractionatedradiotherapyafterconservativesurgerymayincreaselowndashintermediategradelatefibrosisinbreastcancerpatients
AT pierim hypofractionatedradiotherapyafterconservativesurgerymayincreaselowndashintermediategradelatefibrosisinbreastcancerpatients
AT zamagnia hypofractionatedradiotherapyafterconservativesurgerymayincreaselowndashintermediategradelatefibrosisinbreastcancerpatients
AT fariolia hypofractionatedradiotherapyafterconservativesurgerymayincreaselowndashintermediategradelatefibrosisinbreastcancerpatients
AT buwengem hypofractionatedradiotherapyafterconservativesurgerymayincreaselowndashintermediategradelatefibrosisinbreastcancerpatients
AT ferrandinag hypofractionatedradiotherapyafterconservativesurgerymayincreaselowndashintermediategradelatefibrosisinbreastcancerpatients
AT morgantiag hypofractionatedradiotherapyafterconservativesurgerymayincreaselowndashintermediategradelatefibrosisinbreastcancerpatients
_version_ 1718398448354459648

Ejemplares similares